These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027 [TBL] [Abstract][Full Text] [Related]
6. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504 [TBL] [Abstract][Full Text] [Related]
7. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z; Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282 [TBL] [Abstract][Full Text] [Related]
8. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736 [TBL] [Abstract][Full Text] [Related]
9. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490 [TBL] [Abstract][Full Text] [Related]
10. Scoring treatment response in patients with relapsing multiple sclerosis. Sormani MP; Rio J; Tintorè M; Signori A; Li D; Cornelisse P; Stubinski B; Stromillo Ml; Montalban X; De Stefano N Mult Scler; 2013 Apr; 19(5):605-12. PubMed ID: 23012253 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931 [TBL] [Abstract][Full Text] [Related]
12. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825 [TBL] [Abstract][Full Text] [Related]
13. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959 [TBL] [Abstract][Full Text] [Related]
14. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L; N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954 [TBL] [Abstract][Full Text] [Related]
15. The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments. Kieseier BC Expert Rev Neurother; 2014 Jan; 14(1):105-20. PubMed ID: 24417500 [TBL] [Abstract][Full Text] [Related]
16. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. Gauthier SA; Glanz BI; Mandel M; Tsagkaropoulos A; Neema M; Stankiewicz J; Arora A; Duan Y; Liptak Z; Egorova S; Buckle GJ; Bakshi R; Guttmann CR; Khoury SJ; Weiner HL J Neurol Sci; 2009 Sep; 284(1-2):116-9. PubMed ID: 19428028 [TBL] [Abstract][Full Text] [Related]
17. Quantitative MRI and cerebrospinal fluid inflammatory mediators in Brazilian patients with relapsing-remitting multiple sclerosis before and after treatment with immunomodulators: a longitudinal study. Ruocco HH; Brandão CO; Farias AS; Oliveira C; Oliveira EC; Cendes F; Damasceno BP; Santos LM Neuroimmunomodulation; 2012; 19(5):277-82. PubMed ID: 22472803 [TBL] [Abstract][Full Text] [Related]
18. Early predictors of non-response to interferon in multiple sclerosis. Horakova D; Kalincik T; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E Acta Neurol Scand; 2012 Dec; 126(6):390-7. PubMed ID: 22428845 [TBL] [Abstract][Full Text] [Related]